Aderis Pharmaceuticals is Drug Discovery in United States that focus on renal diseases business. They cover business area such as developer, therapeutic, cardiovascular, renal and neurological disease, central nervous system, cardiovascular and renal disease, drug candidate, either block, (antagonist, certain protein, adenosine, dopamine, side effect, small molecule, patient, dosage form, easy formulation, great potential, absorption, utilization.
-
Renal Diseases
-
85 Main Street
Hopkinton, MA 01748
United States
Private
developertherapeuticcardiovascular, renal and neurological diseasecentral nervous systemcardiovascular and renal diseasedrug candidateeither block(antagonistcertain proteinadenosinedopamineside effectsmall moleculepatientdosage formeasy formulationgreat potentialabsorptionutilization
* We use standard office opening hours in near Aderis Pharmaceuticals's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Aderis Pharmaceuticals is Drug Discovery business from United States that founded in - ( years old in ), Aderis Pharmaceuticals business is focusing on Renal Diseases.
Aderis Pharmaceuticals headquarter office and corporate office address is located in 85 Main Street Hopkinton, MA 01748 United States.
Aderis Pharmaceuticals was founded in United States.
In , Aderis Pharmaceuticals is currently focus on renal diseases sector.
Above is snippet of Google Trends for "renal diseases" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Aderis Pharmaceuticals, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
